NadirAlphaNA EN · DE · ES · FR · HI · 中文 · عربي · PL
Advertisement

The Cigna Group CI

SEC filings · Reporting currency USD · Quarterly reporting · Figures as of 2026-Q2 · updated 2026-09-06 · ISIN US1255231003
Guidance raised strategy: Strategic pivot
The new quarter, monitored by AI. · We follow every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.
Advertisement

Business Model#

What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.

The Cigna Group is a global health services organization that operates through two principal segments. Evernorth Health Services delivers pharmacy benefit management through its Pharmacy Benefit Services unit and specialty pharmacy and care delivery through its Specialty and Care Services unit, serving employers, health plans, and government clients. Cigna Healthcare provides employer-sponsored medical, dental, behavioral health, and pharmacy benefits to U.S. commercial customers across National Accounts, Middle Market, and Select employer segments. Revenue is generated through insurance premiums, pharmacy revenues, and fees from benefit administration and service arrangements. Following the 2025 divestiture of Medicare Advantage and related government health businesses to HCSC, and with the announced January 2027 exit from Individual and Family Plans, the company is concentrating its health benefits franchise on commercial employer coverage while expanding pharmacy benefit management and care services through Evernorth.

Advertisement

Current Status#

Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.

Total revenues increased 7% to $71.7 billion in Q2 2026, driven by growth in both Evernorth Health Services and Cigna Healthcare 30. Adjusted income from operations increased 6% to $7.78 per share in Q2 2026 from $7.20 per share in Q2 2025, with Cigna Healthcare adjusted income from operations up 17% and Specialty and Care Services up 22% year over year 30. The company raised its 2026 adjusted income from operations outlook to at least $30.45 per share and, in April 2026, announced a planned exit from the Individual and Family Plans medical business effective January 1, 2027 30.
Management commentary on the 2026-Q2 results (8-K-EX99.1, 2026-07-30):
„Our purpose is to improve the lives of each and every customer and patient we serve. By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day. Our strong second quarter results reflect continued progress against these priorities and demonstrate the effectiveness of our strategy and execution.“ – Brian C. Evanko, President and Chief Executive Officer 30
Revenue · 2026-Q271,668$m+6.7 % vs. 2025-Q2
Net profit · 2026-Q21,660$m+8.4 % vs. 2025-Q2
EPS · 2026-Q26.29$+10.2 % vs. 2025-Q2
Revenue trend
Guidance
For FY2026, the company guides EPS (non-GAAP) to at least $30.45 (raised); Tax rate to ~19.0% (initiated); CapEx to ~$1,300 million (initiated). 30.
Profitability
Operating income for Q2 2026 was $2,676 million, and shareholders' net income was $1,660 million, or $6.29 per share, compared to $5.71 per share in Q2 2025, representing an 8% increase in net income 30. The SG&A expense ratio improved to 4.8% on a GAAP basis and 4.6% on an adjusted basis, versus 5.1% and 4.9%, respectively, in Q2 2025, primarily reflecting operating efficiency 30. Higher adjusted income from operations in Cigna Healthcare was cited as the primary contributor to the net income improvement for the three months ended June 30, 2026 29.
Leverage
As of June 30, 2026, the company held cash of $6,298 million against net debt of $25,580 million. Quarterly operating cash flow was -$421 million, while six-month operating cash flows improved to $710 million compared to $34 million in the prior year period 29. Share repurchases were substantially reduced to 0.9 million shares for approximately $250 million in the six months ended June 30, 2026, compared to 8.2 million shares for approximately $2.6 billion in the same prior year period 29.
Recurring
Insurance premiums increased 8% for the three months ended June 30, 2026, driven by higher premium rates within Cigna Healthcare 29. Pharmacy revenues grew 7% for the three months ended June 30, 2026, reflecting changes in claims composition within Pharmacy Benefit Services, with Pharmacy Benefit Services adjusted revenues up 8% over the same period 29 30. Fees and other revenues increased 6% for the three months ended June 30, 2026, reflecting growth in fee-based services 29.
Management view
Total medical customers increased 2% from December 31, 2025 to 18.4 million as of June 30, 2026, reflecting growth within the Middle Market and Select market segments, partially offset by lower National Accounts membership 30. Cigna Healthcare adjusted revenues increased 9% in Q2 2026 relative to Q2 2025, driven by premium rate increases and improved margin within the U.S. Employer business 30. The 2026 adjusted income from operations outlook was raised to at least $30.45 per share, up from the prior guidance level 30.
Change
Total customer relationships decreased 3% from December 31, 2025 to 182.8 million as of June 30, 2026, and total pharmacy customers fell 4% to 118.2 million, reflecting expected client transitions and lower membership from health plan clients 30. Pharmacy Benefit Services adjusted income from operations decreased 27% in Q2 2026 relative to Q2 2025, reflecting client- and customer-focused investment initiatives 30. Medical costs and other benefit expenses increased 9% for the three months ended June 30, 2026, and the medical care ratio rose 130 basis points, primarily reflecting higher prior year risk adjustment benefits within the Individual and Family Plans business 29.
Risks (current)
Outcome of litigation and regulatory audits and investigations, as well as substantial government regulation and uncertainty around government-sponsored programs participation, represent company-specific legal and regulatory exposures 29. Risks related to strategic transactions – including integration or separation difficulties – remain elevated in the context of recent and pending portfolio changes 21. The ability to maintain relationships with key pharmaceutical manufacturers and manage potential payment declines, together with ongoing health care cost management and margin compression pressures, constitute additional operational risks 29 30.
New this reporting period
In April 2026, the company announced its planned exit from the Individual and Family Plans medical business, with the transition effective January 1, 2027 29 30. This planned divestiture-type action follows the March 2025 completion of the sale of Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses within U.S. Healthcare as part of the HCSC transaction 29. Together, these two transactions mark a strategic withdrawal from government-sponsored and individual market health plans within the U.S. Healthcare segment 29.
Advertisement

Price & Chart#

Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.

Daily candles with news and earnings markers. Loads only on click.

Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.
Advertisement

Share-Price Drivers#

Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.

Evernorth Health Services growth (Pharmacy Benefit Services and Specialty and Care Services)
Evernorth is the dominant revenue engine, with Pharmacy Benefit Services at $33.0bn (+11%) and Specialty and Care Services at $25.4bn (+6%) in the latest quarter, while total revenue rose to $71.7bn in 2026-Q2 with guidance raised 28 29
Pharmacy Benefit Services scale (Evernorth)
Segment revenue $33.0bn, +11% growth; supported by the multi-year Centene pharmacy benefit management agreement effective 2024 28 18
Specialty and Care Services expansion
Segment revenue $25.4bn, +6% growth, extended by the Shields Health Solutions investment and DoD TRICARE Specialty Pharmacy expansion 28 26 10
Rebate-free pharmacy benefit model
New model repeatedly signalled since 2025 with a 2027 launch plan; traction not yet reflected in reported revenue 26 27 24
EnGuide Pharmacy for GLP-1 medications
Launched 2025 to serve GLP-1 demand within Evernorth's specialty offering 26
Portfolio reshaping (Medicare exit, IFP exit)
Sale of Medicare Advantage and related businesses to HCSC completed Q1 2025 and planned exit from Individual and Family Plans medical business effective 2027 remove lower-margin insurance revenue 23 29 30
Capital returns (buybacks and dividend)
Accelerated Share Repurchase agreements and dividend increase reduced diluted shares from ~273m (2025-Q1) toward ~264m (2026-Q2) 13 9

Sector trend: Managed-care KPIs point to top-line demand still accelerating, led by pharmacy and specialty services volumes, while the group prunes lower-margin insurance lines (Medicare, Individual and Family Plans) to lift profitability 28 29 23

Advertisement

Event Timeline#

This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.

Overview: one dot per event · click jumps to the period
earningsrevenuemarginguidancestrategyfinancials2023-Q12023-Q22023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2
2026 · 6 events

2026-Q2 · Apr – Jun 2026

„Our purpose is to improve the lives of each and every customer and patient we serve. By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day. Our strong second quarter results reflect continued progress against these priorities and demonstrate the effectiveness of our strategy and execution.“ – Brian C. Evanko, President and Chief Executive Officer 30
earnings 2026-07-30
Shareholders' net income increased 8% to $1,660 million ($6.29 per share vs. $5.71 in Q2 2025), with adjusted income from operations up 6% to $2.1 billion 30
Guidance raised 2026-07-30
2026 outlook for adjusted income from operations per share raised to at least $30.45, following prior Q1 raise to $30.35 30
Strategic pivot 2026-07-30
In April 2026, company announced planned exit from Individual and Family Plans medical business as of January 1, 2027 30

2026-Q1 · Jan – Mar 2026

„We continue to improve how people experience health care, leveraging innovation and technology to make it more personalized, more transparent and easier to navigate. Our strong first quarter results were driven by disciplined execution, deliberate portfolio shaping and a continued focus on targeted innovation.“ – David M. Cordani, Chairman and CEO 28
earnings 2026-04-30
Shareholders' net income increased 25% to $1,654 million ($6.26 per share vs. $4.85 in Q1 2025), primarily reflecting higher adjusted income from operations in Cigna Healthcare and Evernorth Health Services 27
Margin expanding 2026-04-30
Medical care ratio decreased 240 basis points to 79.8%, primarily due to base effect of HCSC transaction (divestiture of Medicare Advantage and related businesses completed March 19, 2025) 27
Guidance raised 2026-04-30
2026 outlook for adjusted income from operations per share raised to at least $30.35, up $0.10 from prior projection 28
2025 · 15 events

2025-Q4 · Oct – Dec 2025

„In 2025, we expanded access and support, lowered costs, and improved transparency for our customers and patients. As we enter the new year, we are well-positioned to build on this momentum, fueled by our innovations that leverage our diversified businesses and track record of strong financial performance.“ – David M. Cordani, Chairman and CEO 25
earnings 2026-02-05
Full-year adjusted income from operations increased 4% to $8.0 billion ($29.84 per share) from $7.7 billion ($27.33 per share) in 2024 25
Margin compressing 2026-02-05
Cigna Healthcare full-year MCR was 84.4% compared to 83.2% in 2024, primarily due to higher medical costs driven by the Individual and Family Plans business 25
Guidance initiated 2026-02-05
2026 outlook established with adjusted income from operations of at least $7.950 billion, or at least $30.25 per share 25

2025-Q3 · Jul – Sep 2025

„Our strong quarterly results reflect the breadth of our businesses and focused execution on our growth strategy, even in a dynamic environment. We continue to lead positive change and are addressing some of healthcare's biggest challenges. Our new market-defining rebate-free pharmacy benefit model will further lower costs and enhance transparency for the benefit of those we serve.“ – David M. Cordani, Chairman and CEO 24
revenue 2025-10-30
Total revenues increased 10% to $69.7 billion, primarily driven by Evernorth Health Services growth 24
Margin compressing 2025-10-30
Cigna Healthcare MCR increased to 84.8% from 82.8% in Q3 2024, driven by Individual and Family Plans business and higher stop loss medical costs 24
Strategic pivot 2025-10-30
Evernorth Health Services announced transformational rebate-free pharmacy benefit model designed to lower drug costs, improve transparency, and support local pharmacies 24
Net income doubled 2025-10-30
Net income more than doubled YoY (739.0 to 1,868.0 USDm, +153%). 23
Cash flow inflection 2025-10-30
Operating cash flow reached 3,418.0 USDm vs 46.0 USDm in 2024-Q3 (×74.3). 23

2025-Q2 · Apr – Jun 2025

„Listening, adapting, and innovating to meet the evolving needs of our patients, customers, and clients enables us to deliver meaningful value. Our performance in the second quarter reflects our disciplined execution and the strength of our business mix.“ – David M. Cordani, Chairman and CEO 22
revenue 2025-07-31
Total revenues increased 11% to $67.2 billion, primarily driven by Evernorth Health Services including growth of existing client relationships and strong specialty pharmacy growth 22
Margin compressing 2025-07-31
Cigna Healthcare MCR was 83.2% for Q2 2025 compared to 82.3% for Q2 2024, primarily due to expected higher stop loss medical costs 22
Guidance confirmed 2025-07-31
2025 outlook for adjusted income from operations of at least $29.60 per share reaffirmed 22

2025-Q1 · Jan – Mar 2025

„We are building a more sustainable health care model by successfully delivering on our series of commitments and actions to improve transparency and support for our customers and patients. Our strong first quarter results and increase in outlook for full-year earnings reflects the strength of our Evernorth Health Services and Cigna Healthcare growth platforms in a dynamic environment.“ – David M. Cordani, Chairman and CEO 20
Margin compressing 2025-05-02
Cigna Healthcare MCR rose to 82.2% from 79.9% in Q1 2024, primarily driven by expected higher stop loss medical costs 20
Guidance raised 2025-05-02
2025 adjusted income from operations guidance raised to at least $29.60 per share 20
Divestiture 2025-05-02
Divestiture of Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to HCSC completed for $4.8 billion purchase price 19
Revenue decelerating 2025-05-02
Revenue growth decelerated to +14.4% YoY (prior period +28.4%). 19
2024 · 13 events

2024-Q4 · Oct – Dec 2024

„While higher medical costs in our stop loss product impacted fourth quarter earnings, we are taking corrective actions to address these near-term pressures and we are simultaneously taking steps to further advance our long-term growth strategy. Through a dynamic environment, we are continuing to focus on building a sustainable model for healthcare by addressing the areas that matter most to our patients and clients, including greater transparency, support, and value.“ – David M. Cordani, Chairman and Chief Executive Officer 17
earnings 2025-01-30
Q4 adjusted income from operations decreased 8% from Q4 2023, primarily driven by lower Cigna Healthcare contributions due to higher stop loss medical costs 17
revenue 2025-01-30
Full year 2024 revenues +27% to $247.1B; total customer relationships increased 11% to 182.2 million and pharmacy customers grew 22% to 120.0 million driven by Evernorth Health Services expansion 17
Margin compressing 2025-01-30
Full year Cigna Healthcare MCR increased to 83.2% from 81.3% in 2023, primarily driven by higher stop loss medical costs, contributing to a 6% full-year decline in Cigna Healthcare adjusted income from operations 17
Cash flow inflection 2025-01-30
Operating cash flow reached 5,212.0 USDm vs 1,467.0 USDm in 2023-Q4 (×3.6). 125

2024-Q3 · Jul – Sep 2024

„Our strong performance this quarter is a testament to the leadership, stability and expertise of our team. Our disciplined execution of our strategic plan and our comprehensive health services ensure we remain well-positioned in a highly dynamic environment, while sustaining business growth in both the near- and long-term.“ – David M. Cordani, Chairman and Chief Executive Officer 16
earnings 2024-10-31
Q3 adjusted income from operations $7.51/share vs $6.77/share in Q3 2023, with Evernorth Health Services up 9% and Specialty and Care Services up 23%; Cigna Healthcare down 4% driven by higher MCR 16
earnings 2024-10-31
Q3 shareholders' net income $2.63/share, reduced by a $1.0B non-cash after-tax investment loss from a second impairment of VillageMD equity securities 16
Revenue accelerating 2024-10-31
Q3 revenues +30% to $63.7B, driven by Evernorth Health Services large client wins, specialty volume growth, and increased Humira biosimilar adoption 16

2024-Q2 · Apr – Jun 2024

„Our second quarter results underscore the strength of our diversified portfolio. We continue to deliver innovative solutions to meet the evolving needs of those we serve. We remain disciplined in our approach to executing our strategy, enabling us to consistently deliver value and sustain our growth in a dynamic environment.“ – David M. Cordani, Chairman and CEO 14
earnings 2024-08-01
Q2 adjusted income from operations $6.72/share vs $6.13/share in Q2 2023, reflecting Evernorth Health Services growth of 30% in adjusted revenues and 7% in adjusted income 14
Revenue accelerating 2024-08-01
Q2 revenues +25% to $60.5B, driven by Evernorth Health Services Pharmacy Benefit Services reflecting large client wins including Centene and organic growth; Pharmacy Benefit Services adjusted revenues +41% 14
Margin compressing 2024-08-01
Cigna Healthcare MCR 82.3% in Q2, including approximately 40 bps of unfavorable prior-year Medicare Advantage risk adjustment revenue impacts 14

2024-Q1 · Jan – Mar 2024

„Our strong first quarter results reflect the performance of our Evernorth and Cigna Healthcare businesses, as well as our leadership in addressing the evolving needs of those we serve with the breadth of our differentiated capabilities. Building on our track record of growth and continued momentum in 2024, we are pleased to increase our outlook for full-year earnings.“ – David M. Cordani, Chairman and CEO 12
Net income turned negative 2024-05-02
Shareholders' net loss of $0.97/share in Q1, including a $1.8B non-cash after-tax investment loss from impairment of VillageMD equity securities 12
Revenue accelerating 2024-05-02
Q1 revenues +23% YoY, driven by Centene Corporation onboarding at the start of 2024, which increased pharmacy revenues 31% within Evernorth Health Services 11
Divestiture 2024-05-02
Definitive agreement signed to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for approximately $3.7 billion, expected to close Q1 2025 11
2023 · 13 events

2023-Q4 · Oct – Dec 2023

„2023 was another very strong year for our company with consistent execution and sustained growth. We will accelerate our momentum in 2024 as we lead in improving value, affordability and clinical outcomes, as well as with expanding access and choice.“ – David M. Cordani, Chairman and CEO 9
Divestiture 2024-02-29
Entered definitive agreement to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to Health Care Service Corporation for $3.3 billion cash, subject to regulatory approvals (10)
Revenue accelerating 2024-02-02
Full-year 2023 revenues reached $195.3 billion, up from $180.5 billion in 2022; adjusted income from operations $7.4 billion ($25.09 per share) vs. $7.3 billion ($23.36 per share) in prior year (9)
Guidance initiated 2024-02-02
2024 adjusted income from operations guidance initiated at at least $8.025 billion, or at least $28.25 per share (9)

2023-Q3 · Jul – Sep 2023

„We continued to drive growth in the third quarter by harnessing our deep clinical expertise and service capabilities across our company, supporting high-quality care, improved affordability and better outcomes. With disciplined execution and continued innovation across Evernorth Health Services and Cigna Healthcare, we're meeting the evolving needs of those we serve.“ – David M. Cordani, Chairman and Chief Executive Officer 8
earnings 2023-11-02
Adjusted income from operations increased 8% to $2.0 billion ($6.77 per share), reversing the year-over-year declines in Q1 and Q2 that had reflected the absence of businesses divested in the 2022 Chubb transaction (8)
Revenue accelerating 2023-11-02
Total revenues increased 8% to $49.0 billion; Evernorth Health Services adjusted revenues up 8% and Cigna Healthcare adjusted revenues up 14%, with premiums up 15% reflecting insured customer growth (8)
Guidance raised 2023-11-02
2023 adjusted EPS outlook raised to at least $24.75 per share from prior projection of at least $24.70 (8)

2023-Q2 · Apr – Jun 2023

„We're pleased with our performance and growth across the breadth of our business in the second quarter as our co-workers continued to drive innovation and deliver effective and affordable solutions supporting the health and vitality of our customers, patients and clients.“ – David M. Cordani, Chairman and Chief Executive Officer 6
Revenue accelerating 2023-08-03
Total revenues increased 7% to $48.6 billion; Evernorth Health Services adjusted revenues up 10% and Cigna Healthcare adjusted revenues up 12%, driven by specialty growth and customer expansion (6)
Guidance raised 2023-08-03
2023 full-year adjusted revenue guidance raised to at least $190.0 billion; operating cash flow guidance raised to at least $9.5 billion (6)
Acquisition 2023-08-03
Evernorth Health became minority owner in CarepathRx Health Systems Solutions through a $437 million equity method investment in July 2023 to provide integrated hospital pharmacy solutions (5)

2023-Q1 · Jan – Mar 2023

„Our strong results in the first quarter demonstrate how our company continues to execute well, while also introducing innovative, market-leading solutions that improve clinical outcomes, affordability and transparency for the benefit of those we serve“ – David M. Cordani, Chairman and Chief Executive Officer 4
Revenue accelerating 2023-05-05
Total revenues increased 6% to $46.5 billion; Evernorth adjusted revenues up 8% and Cigna Healthcare adjusted revenues up 12%, reflecting specialty pharmacy growth and insured customer expansion (4)
Margin expanding 2023-05-05
Cigna Healthcare medical care ratio decreased 20 basis points to 81.3%, reflecting effective pricing execution and favorable cost trends including lower COVID-19 costs (3)
Guidance raised 2023-05-05
2023 adjusted income from operations outlook raised to at least $24.70 per share (4)
Cash flow inflection 2023-05-05
Operating cash flow reached 5,028.0 USDm vs 2,030.0 USDm in 2022-Q1 (×2.5). 3
Advertisement

Key Figures ($m)#

The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.

Revenue ($m) · annual basis, as reported
FY2023FY2023: 195,265195,265FY2024FY2024: 247,121247,121FY2025FY2025: 274,900274,900
Net income ($m) · annual basis, as reported
FY2023FY2023: 5,1645,164FY2024FY2024: 3,4343,434FY2025FY2025: 5,9575,957
EPS ($) · annual basis, as reported
FY2023FY2023: 17.3917.39FY2024FY2024: 12.1212.12FY2025FY2025: 22.1822.18
Operating cash flow ($m) · annual basis, as reported
FY2023FY2023: 11,81311,813FY2024FY2024: 10,36310,363FY2025FY2025: 9,6019,601
Revenue ($m) · quarterly basis, as reported
2024-Q32024-Q3: 63,69463,6942024-Q42024-Q4: 65,64965,6492025-Q12025-Q1: 65,50265,5022025-Q22025-Q2: 67,17867,1782025-Q32025-Q3: 69,74869,7482025-Q42025-Q4: 72,47272,4722026-Q12026-Q1: 68,49468,4942026-Q22026-Q2: 71,66871,668
Net income ($m) · quarterly basis, as reported
2024-Q32024-Q3: 7397392024-Q42024-Q4: 1,4241,4242025-Q12025-Q1: 1,3231,3232025-Q22025-Q2: 1,5321,5322025-Q32025-Q3: 1,8681,8682025-Q42025-Q4: 1,2341,2342026-Q12026-Q1: 1,6541,6542026-Q22026-Q2: 1,6601,660
EPS ($) · quarterly basis, as reported
2024-Q32024-Q3: 2.632.632024-Q42024-Q4: 5.035.032025-Q12025-Q1: 4.854.852025-Q22025-Q2: 5.715.712025-Q32025-Q3: 6.986.982025-Q42025-Q4: 4.594.592026-Q12026-Q1: 6.266.262026-Q22026-Q2: 6.296.29
Operating cash flow ($m) · quarterly basis, as reported
2024-Q32024-Q3: 46462024-Q42024-Q4: 5,2125,2122025-Q12025-Q1: 1,9201,9202025-Q22025-Q2: -1,886-1,8862025-Q32025-Q3: 3,4183,4182025-Q42025-Q4: 6,1496,1492026-Q12026-Q1: 1,1311,1312026-Q22026-Q2: -421-421
Cash ($m) · annual basis, as reported
FY2023FY2023: 7,8227,822FY2024FY2024: 7,5507,550FY2025FY2025: 7,6767,676
Debt ($m) · annual basis, as reported
FY2023FY2023: 30,93030,930FY2024FY2024: 31,97231,972FY2025FY2025: 31,46331,463
Net Debt ($m) · annual basis, as reported
FY2023FY2023: 23,10823,108FY2024FY2024: 24,42224,422FY2025FY2025: 23,78723,787
D&A ($m) · annual basis, as reported
FY2023FY2023: 3,0353,035FY2024FY2024: 2,7752,775FY2025FY2025: 2,7752,775
Cash ($m) · quarterly basis, as reported
2024-Q32024-Q3: 5,8885,8882024-Q42024-Q4: 7,5507,5502025-Q12025-Q1: 8,3348,3342025-Q22025-Q2: 4,3294,3292025-Q32025-Q3: 6,0256,0252025-Q42025-Q4: 7,6767,6762026-Q12026-Q1: 7,0407,0402026-Q22026-Q2: 6,2986,298
Debt ($m) · quarterly basis, as reported
2024-Q32024-Q3: 32,80232,8022024-Q42024-Q4: 31,97231,9722025-Q12025-Q1: 30,44830,4482025-Q22025-Q2: 30,76830,7682025-Q32025-Q3: 34,04034,0402025-Q42025-Q4: 31,46331,4632026-Q12026-Q1: 30,90030,9002026-Q22026-Q2: 31,87831,878
Net Debt ($m) · quarterly basis, as reported
2024-Q32024-Q3: 26,91426,9142024-Q42024-Q4: 24,42224,4222025-Q12025-Q1: 22,11422,1142025-Q22025-Q2: 26,43926,4392025-Q32025-Q3: 28,01528,0152025-Q42025-Q4: 23,78723,7872026-Q12026-Q1: 23,86023,8602026-Q22026-Q2: 25,58025,580
D&A ($m) · quarterly basis, as reported
2024-Q32024-Q3: 6506502024-Q42024-Q4: 6466462025-Q12025-Q1: 6746742025-Q22025-Q2: 6826822025-Q32025-Q3: 6976972025-Q42025-Q4: 7227222026-Q12026-Q1: 6506502026-Q22026-Q2: 655655
Shown: the most recent fiscal years. Full history since FY2017 is on record.

Fiscal years

Amounts in $m · EPS in $ per share · as reported
PeriodRevenueOp. incomeOp. income (adj.)Net incomeEPS ($)OCFSource
FY2025274,9009,200-387.895,95722.189,60126
FY2024247,1219,4177,7413,43412.1210,36318
FY2023195,2658,5367,4485,16417.3911,81310

Quarters

Amounts in $m · EPS in $ per share · Net Debt/EBITDA as a multiple · as reported
PeriodPublishedRevenueOp. incomeOp. income (adj.)Net incomeEPS ($)CashNet DebtNet Debt/EBITDA (x)Source
2026-Q2*2026-07-3071,6682,6767.781,6606.296,29825,5802x (LTM)29
2026-Q1*2026-04-3068,4942,3582,0581,6546.267,04023,8601.9x (LTM)27
2025-Q4*2026-02-0572,4722,3458.081,2344.59*7,67623,7872x (LTM)25
2025-Q3*2025-10-3069,7482,5787.831,8686.986,02528,0152.4x (LTM)23
2025-Q2*2025-07-3167,1782,3067.21,5325.714,32926,4392.3x (LTM)21
2025-Q1*2025-05-0265,5021,971-4111,3234.858,33422,1141.9x (LTM)19
2024-Q4*2025-01-3065,6492,1731,8451,4245.03*7,55024,4222x (LTM)17
2024-Q3*2024-10-3163,6942,5762,1127392.635,88826,9142.2x (LTM)15
2024-Q2*2024-08-0160,5232,4121,9091,5485.456,78825,1042.1x (LTM)13
2024-Q1*2024-05-0257,2552,2566.47-277-0.978,43924,3292.1x (LTM)11
2023-Q4*2024-02-2951,1142,0607,429.71,0293.47*7,82223,1082x (LTM)10
2023-Q3*2023-11-0249,0482,2402,0001,4084.748,49722,6432x (LTM)7
2023-Q2*2023-08-0348,5862,2211,8201,4604.929,58523,1482.1x (LTM)5
2023-Q1*2023-05-0546,5172,0151,1151,2674.247,93524,6072.2x (LTM)3
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Columns not reported in this reporting cadence are hidden: EBITDA (adj.), EPS adj., FCF (not reported in any source for these periods).
Advertisement

Balance Sheet & Cash Flow ($m)#

Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

Fiscal years

Amounts in $m · as reported
PeriodPublishedCashDebtNet DebtD&AOCFSource
FY20252026-02-267,67631,46323,7872,7759,60126
FY20242025-01-307,55031,97224,4222,77510,36317
FY20232024-02-297,82230,93023,1083,03511,81310

Quarters

Amounts in $m · as reported
PeriodPublishedCashDebtNet DebtD&AOCFSource
2026-Q22026-07-306,29831,87825,580655-42129
2026-Q12026-04-307,04030,90023,8606501,13127
2025-Q42026-02-057,67631,46323,7877226,14925
2025-Q32025-10-306,02534,04028,0156973,41823
2025-Q22025-07-314,32930,76826,439682-1,88621
2025-Q12025-05-028,33430,44822,1146741,92019
2024-Q42025-01-307,55031,97224,4226465,21217
2024-Q32024-10-315,88832,80226,9146504615
2024-Q22024-08-016,78831,89225,10473826513
2024-Q12024-05-028,43932,76824,3297414,84011
2023-Q42024-02-297,82230,93023,1087651,46710
2023-Q32023-11-028,49731,14022,6437662,8267
2023-Q22023-08-039,58532,73323,1487552,4925
2023-Q12023-05-057,93532,54224,6077495,0283
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.
Advertisement

Revenue by Type (as of 2026-Q2 · USDm · 4/6)#

Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.

SegmentSincePeriodBasisRevenueGrowthMarginSource
Other Operations2023-Q12026-Q23M131-29%16%29
Pharmacy Benefit Services2024-Q12026-Q13M33,00211%28
Specialty and Care Services2024-Q12026-Q13M25,4406%28
Evernorth Health Services2022-Q22026-Q13M58,4429%2.5%28
Evernorth Health Services - Pharmacy Benefit Services2024-Q2FY20243M111,82246%18
Evernorth Health Services - Specialty and Care Services2024-Q2FY20243M90,33318%18
Advertisement

Products & M&A (4/7 active+recent)#

Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.

Product/LineSinceStatusSource
Rebate-free model business plan2026-03Launched27
Rebate-free pharmacy benefit model (2x)2025-09Launched26
Strategic Optimization Program2025-03Launched26
EnGuide Pharmacy for GLP-1 medications2025Launched26
DoD TRICARE Specialty Pharmacy expansion2024Launched10
The Cigna Group Ventures strategic venture fund (2x)2023Launched18
Pathwell Bone & Joint product launch2023Launched10
Advertisement

M&A (20)#

All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.

Acquisitions · 7Divestitures/exits · 4older: 9 (in the table)
2024202520262027

Acquisitions

Transaction / stakeDateTypeSource
Shields Health Solutions investment2025-08Completed26
Dividend Increase2024-02Completed9
Centene Corporation Onboarding2024-01Completed11
Organizational Efficiency Plan2024Completed9
Express Scripts and Prime Therapeutics LLC agreement for pharmacy network and specialty pharmacy services2024Announced18
Centene multi-year pharmacy benefit agreement (3×)2024Announced18
Accelerated Share Repurchase Agreements (2×)2024Announced13
Senior notes repayment2023-07Completed5
5.685% senior notes issuance (3×)2023-03Completed13
VillageMD investment (6×)2023Completed18
Share repurchase program2023Completed8
CarepathRx Health Systems Solutions minority ownership investment (2×)2023Completed5

Divestitures / exits

Transaction / stakeDateTypeSource
Exit from Individual and Family Plans medical business (2×)2027-01Divested29
HCSC transaction2025-03Divested26
HCSC transaction - Sale of Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, and CareAllies businesses (13×)2024-01Divested10
Sale of Medicare businesses to HCSC (7×)2024Divested23
New York Life supplemental behavioral coverage contract non-renewal2023Divested8
Chubb transaction - sale of life, accident and supplemental health benefits business2022-07Divested7
Joint venture in Türkiye divestiture2022Divested10
Chubb international life insurance and supplemental benefits sale2022Divested10
Advertisement

Reported KPIs (as disclosed) (360)#

Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.

Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
DatePeriodKPIValue / changeSource
2026-07-302026-Q2Unpaid claims and claim expenses5,228 (USD millions)29
2026-07-302026-Q2Undrawn committed capacity under revolving credit agreement6.529
2026-07-302026-Q2Total revenues71,668 (USD millions)29
2026-07-302026-Q2Total medical customers18,41329
2026-07-302026-Q2Total Pharmacy Customers118,24330
2026-07-302026-Q2Total Medical Customers18,41330
2026-07-302026-Q2Total Customer Relationships182,76530
2026-07-302026-Q2Share repurchases25029
2026-07-302026-Q2Premiums9,85929
2026-07-302026-Q2Pharmacy revenues57,172 (USD millions)29
2026-07-302026-Q2Other long-term investments5.2 (USD billions)29
2026-07-302026-Q2Net investment income272 (USD millions)29
2026-07-302026-Q2Medical care ratio84.5%29
2026-07-302026-Q2Fees and other revenues4,365 (USD millions)29
2026-07-302026-Q2Dental Customers18,48830
2026-07-302026-Q2Debt-to-capitalization ratio42.8%29
2026-07-302026-Q2Debt securities portfolio carrying value8.5 (USD billions)29
2026-07-302026-Q2Commercial paper program outstanding balance1.029
2026-07-302026-Q2Commercial mortgage loan portfolio1.2 (USD billions)29
2026-07-302026-Q2Cigna Healthcare Medical Care Ratio84.5%30
2026-07-302026-Q2Cash and short-term investments6.6 (USD billions)29
2026-07-302026-Q2Capital expenditures0.6 (USD billions)29
2026-07-302026-Q2Behavioral Care Customers27,62130
2026-04-302026-Q1Unpaid claims and claim expenses$4,92027
2026-04-302026-Q1Undrawn committed capacity revolving credit$6.5 billion27
2026-04-302026-Q1Other long-term investments$5.2 billion27
2026-04-302026-Q1Medical customers total18,33427
2026-04-302026-Q1Debt to capitalization ratio42.3%27
2026-04-302026-Q1Commercial mortgage loan portfolio$1.3 billion27
2026-04-302026-Q1Cash and short-term investments$7.3 billion27
2026-04-302026-Q1Total Pharmacy Customers121,02028
2026-04-302026-Q1Total Medical Customers18,33428
2026-04-302026-Q1Total Customer Relationships185,47028
2026-04-302026-Q1Specialty and Care Services Adjusted Revenues25,440 (USD millions)28
2026-04-302026-Q1Shareholders' Equity Per Share159.5928
2026-04-302026-Q1Shareholders' Equity42,21028
2026-04-302026-Q1SG&A Expense Ratio5.4%28
2026-04-302026-Q1Pharmacy Benefit Services Adjusted Revenues33,002 (USD millions)28
2026-04-302026-Q1Evernorth Health Services Adjusted Revenues58,442 (USD millions)28
2026-04-302026-Q1Debt-to-Capitalization Ratio42.3%28
2026-04-302026-Q1Cigna Healthcare Medical Care Ratio79.8%28
2026-04-302026-Q1Cigna Healthcare Adjusted Revenues11,477 (USD millions)28
2026-04-302026-Q1Adjusted SG&A Expense Ratio4.8%28
2026-02-26FY2025Voluntary Turnover Rate9%26
2026-02-26FY2025US Patentsover 54026
2026-02-26FY2025US Network Physicians1.7 million26
2026-02-26FY2025US Network Hospitalsover 6,00026
2026-02-26FY2025US Federal Government Revenue % 202411%26
2026-02-26FY2025US Federal Government Revenue % 202315%26
2026-02-26FY2025US Ethnic Minorities %40%26
2026-02-26FY2025Underrepresented-to-White Wage Ratio USmore than 99 cents per dollar26
2026-02-26FY2025Specialty Pharmacies35 licensed pharmacies26
2026-02-26FY2025Specialist Group Arrangementsapproximately 10026
2026-02-26FY2025Single Pharmacy Benefit Client Revenue % 202519%26
2026-02-26FY2025Single Pharmacy Benefit Client Revenue % 202416%26
2026-02-26FY2025Primary Care Value-Based Arrangementsmore than 20026
2026-02-26FY2025Pharmacy Claims Processing Capacityover two billion adjusted prescriptions annually26
2026-02-26FY2025Pharmaceutical Purchases Single Wholesaler %approximately 50%26
2026-02-26FY2025markets and jurisdictionsmore than 3026
2026-02-26FY2025insured segment revenue percentage 202568%26
2026-02-26FY2025insured medical customers percentage 202521%26
2026-02-26FY2025individual family plans states11 states26
2026-02-26FY2025hospital system hospitals coveredmore than 75026
2026-02-26FY2025hospital system contractsmore than 20026
2026-02-26FY2025home delivery pharmacy locations11 licensed pharmacies26
2026-02-26FY2025home delivery pharmacy fulfillment centers426
2026-02-26FY2025healthcare providers relationships1.7 million26
2026-02-26FY2025health system services distribution centers426
2026-02-26FY2025health benefits payroll investment percentage20%26
2026-02-26FY2025female to male wage ratio USmore than 99 cents per dollar26
2026-02-26FY2025female to male wage ratio globalmore than 99 cents per dollar26
2026-02-26FY2025Express Scripts rebate sharing percentage 2025over 95%26
2026-02-26FY2025Express Scripts clients receiving 100 percent rebatesmore than two-thirds26
2026-02-26FY2025Enguide pharmacy locations2 licensed pharmacies26
2026-02-26FY2025Enguide pharmacy fulfillment centers126
2026-02-26FY2025dental IFP states49 states26
2026-02-26FY2025customer relationships185 million26
2026-02-26FY2025ASO segment revenue percentage 202532%26
2026-02-26FY2025ASO medical customers percentage 202579%26
2026-02-26FY2025Unpaid claims and claim expenses$4,24126
2026-02-26FY2025Undrawn committed capacity$6.5 billion26
2026-02-26FY2025Total medical customers18,11826
2026-02-26FY2025Debt to capitalization ratio43.0%26
2026-02-052025-Q4Total Pharmacy Customers123,60325
2026-02-052025-Q4Total Medical Customers18,11825
2026-02-052025-Q4Total Customer Relationships188,42825
2026-02-052025-Q4Shareholders' Equity per Share$158.3325
2026-02-052025-Q4SG&A Expense Ratio (Q4 2025)5.0%25
2026-02-052025-Q4SG&A Expense Ratio (FY 2025)5.3%25
2026-02-052025-Q4Dental Customers18,43825
2026-02-052025-Q4Debt-to-Capitalization Ratio43.0%25
2026-02-052025-Q4Cigna Healthcare Medical Care Ratio (Q4 2025)88.0%25
2026-02-052025-Q4Cigna Healthcare Medical Care Ratio (FY 2025)84.4%25
2026-02-052025-Q4Behavioral Care Customers28,26925
2026-02-052025-Q4Adjusted SG&A Expense Ratio (Q4 2025)4.7%25
2026-02-052025-Q4Adjusted SG&A Expense Ratio (FY 2025)5.0%25
2025-10-302025-Q3Unpaid claims and claim expenses$4,67623
2025-10-302025-Q3Total Pharmacy Customers122,48624
2025-10-302025-Q3Total Medical Customers18,05924
2025-10-302025-Q3Total Customer Relationships182,49024
2025-10-302025-Q3Medical customers18,05923
2025-10-302025-Q3Debt-to-capitalization ratio44.9%23
2025-10-302025-Q3Cigna Healthcare Medical Care Ratio84.8%24
2025-07-312025-Q2Total revenues (3 months)67,178 (USD in millions)21
2025-07-312025-Q2Total revenues (6 months)132,680 (USD in millions)21
2025-07-312025-Q2Total income taxes (3 months)389 (USD in millions)21
2025-07-312025-Q2Total income taxes (6 months)628 (USD in millions)21
2025-07-312025-Q2Shareholders' net income (3 months)1,53221
2025-07-312025-Q2Shareholders' net income (6 months)2,85521
2025-07-312025-Q2Premiums (3 months)9,15621
2025-07-312025-Q2Premiums (6 months)21,89221
2025-07-312025-Q2Pharmacy revenues (3 months)53,649 (USD in millions)21
2025-07-312025-Q2Pharmacy revenues six months102,282 (USD in millions)21
2025-07-312025-Q2Pharmacy and other service costs three months53,268 (USD in millions)21
2025-07-312025-Q2Pharmacy and other service costs six months101,666 (USD in millions)21
2025-07-312025-Q2Net investment income three months236 (USD in millions)21
2025-07-312025-Q2Net investment income six months474 (USD in millions)21
2025-07-312025-Q2Net investment gains/losses three months52 (USD in millions)21
2025-07-312025-Q2Net investment gains/losses six months50 (USD in millions)21
2025-07-312025-Q2Net income three months1,632 (USD in millions)21
2025-07-312025-Q2Net income six months3,041 (USD in millions)21
2025-07-312025-Q2Net income attributable to noncontrolling interests three months100 (USD in millions)21
2025-07-312025-Q2Net income attributable to noncontrolling interests six months186 (USD in millions)21
2025-07-312025-Q2Medical customers thousands18,04621
2025-07-312025-Q2Medical costs and other benefit expenses three months7,749 (USD in millions)21
2025-07-312025-Q2Medical costs and other benefit expenses six months18,247 (USD in millions)21
2025-07-312025-Q2Interest expense and other three months(337)21
2025-07-312025-Q2Interest expense and other six months(699)21
2025-07-312025-Q2Income from operations three months2,30621
2025-07-312025-Q2Income from operations six months4,27721
2025-07-312025-Q2Income before income taxes three months2,021 (USD in millions)21
2025-07-312025-Q2Income before income taxes six months3,669 (USD in millions)21
2025-07-312025-Q2Gain (Loss) on Sale of Businesses (3M)21
2025-07-312025-Q2Gain (Loss) on Sale of Businesses (6M)4121
2025-07-312025-Q2Fees and Other Revenues (3M)4,137 (USD in millions)21
2025-07-312025-Q2Fees and Other Revenues (6M)8,032 (USD in millions)21
2025-07-312025-Q2Effective Tax Rate (3M)19.2 %21
2025-07-312025-Q2Effective Tax Rate (6M)17.1 %21
2025-07-312025-Q2Consolidated Effective Tax Rate 2024 (3M)18.1 %21
2025-07-312025-Q2Consolidated Effective Tax Rate 2024 (6M)31.5 %21
2025-07-312025-Q2Total Pharmacy Customers121,89222
2025-07-312025-Q2Total medical customers18,04622
2025-07-312025-Q2Total Customer Relationships182,23622
2025-07-312025-Q2Cigna Healthcare Medical Care Ratio83.2%22
2025-05-022025-Q1Unpaid claims and claim expenses4,508 (USD in millions)19
2025-05-022025-Q1U.S. Healthcare Medical Customers16,36420
2025-05-022025-Q1Total Pharmacy Customers122,28320
2025-05-022025-Q1Total Medical Customers18,04320
2025-05-022025-Q1Total Customer Relationships182,20820
2025-05-022025-Q1SG&A Expense Ratio6.4%20
2025-05-022025-Q1Medical customers18,04319
2025-05-022025-Q1International Health Medical Customers1,67920
2025-05-022025-Q1Evernorth Health Services Margin, Pre-Tax2.7%20
2025-05-022025-Q1Dental Customers18,46620
2025-05-022025-Q1Debt-to-capitalization ratio43.1%19
2025-05-022025-Q1Cigna Healthcare Medical Care Ratio82.2%20
2025-05-022025-Q1Cigna Healthcare Margin, Pre-Tax8.9%20
2025-05-022025-Q1Behavioral Care Customers23,41620
2025-05-022025-Q1Adjusted SG&A Expense Ratio5.8%20
2025-02-27FY2024Voluntary Turnover Rateapproximately 9%18
2025-02-27FY2024U.S. Physician Networkapproximately 1.8 million18
2025-02-27FY2024US Patentsover 48018
2025-02-27FY2024U.S. Federal Government Revenue 2024 (%)approximately 11%18
2025-02-27FY2024U.S. Federal Government Revenue 2023 (%)15%18
2025-02-27FY2024U.S. Federal Government Revenue 2022 (%)14%18
2025-02-27FY2024Specialty Pharmacies35 licensed pharmacies18
2025-02-27FY2024single pharmacy client revenue percentageapproximately 16%18
2025-02-27FY2024settlement annuity guaranteed payments percentageapproximately 12%18
2025-02-27FY2024retail pharmacy networksnational and regional network options18
2025-02-27FY2024provider value based arrangements specialistapproximately 10018
2025-02-27FY2024provider value based arrangements primary caremore than 20018
2025-02-27FY2024payroll invested in benefits percentageapproximately 19%18
2025-02-27FY2024medicare supplement plans states48 states and the District of Columbia18
2025-02-27FY2024medicare advantage plans states29 states and the District of Columbia18
2025-02-27FY2024insured segment revenue percentageapproximately 74%18
2025-02-27FY2024insured medical customers percentage26%18
2025-02-27FY2024ifp plans states11 states18
2025-02-27FY2024hospitals in contractsmore than 80018
2025-02-27FY2024hospital system contractsmore than 20018
2025-02-27FY2024hospital networkover 6,00018
2025-02-27FY2024home delivery pharmacies13 licensed pharmacies, including 4 fulfillment pharmacies18
2025-02-27FY2024ethnic minority pay equity usmore than 99 cents18
2025-02-27FY2024dental ifp plans states49 states18
2025-02-27FY2024customer patient relationshipsapproximately 182 million18
2025-02-27FY2024cigna ventures commitment700 million18
2025-02-27FY2024centene rebates shared percentageover 95%18
2025-02-27FY2024centene clients 100pct rebates percentagemore than two-thirds18
2025-02-27FY2024ASO Segment Revenue %approximately 26%18
2025-02-27FY2024ASO Medical Customers %74%18
2025-02-27FY2024Adjusted Prescriptions Annuallyover 2 billion18
2025-02-27FY2024Valuation Allowances 2024$2,332 million18
2025-02-27FY2024Valuation Allowances 2023$1,498 million18
2025-02-27FY2024Unpaid Claims Net 2024$4,859 million18
2025-02-27FY2024Unpaid Claims Net 2023$4,856 million18
2025-02-27FY2024Unpaid Claims Gross 2024$5,018 million18
2025-02-27FY2024Unpaid Claims Gross 2023$5,092 million18
2025-02-27FY2024Undrawn Committed Capacity$6.5 billion18
2025-02-27FY2024Uncertain Tax Positions$1.5 billion18
2025-02-27FY2024Total Share Repurchase Authority$10.3 billion18
2025-02-27FY2024Tax Position Balances 2024$1,477 million18
2025-02-27FY2024Tax Position Balances 2023$1,399 million18
2025-02-27FY2024Subsidiary Borrowing Capacity$1.8 billion18
2025-02-27FY2024Shares Repurchased 2025 YTD3.0 million18
2025-02-27FY2024Shares Repurchased 202420.9 million18
2025-02-27FY2024Shares Repurchased 20237.8 million18
2025-02-27FY2024Share Repurchase Amount 2025 YTD$901 million18
2025-02-27FY2024Share Repurchase Amount 2024$7.0 billion18
2025-02-27FY2024Share Repurchase Amount 2023$2.3 billion18
2025-02-27FY2024Service Commitments 2025$0.7 billion18
2025-02-27FY2024Remaining Share Repurchase Authority$9.4 billion18
2025-02-27FY2024Remaining Commercial Paper Capacity$5.6 billion18
2025-02-27FY2024Purchase Obligations Total$4.2 billion18
2025-02-27FY2024Purchase Obligations Next 12 Months$1.6 billion18
2025-02-27FY2024Potential Tax Payments$1.0 billion18
2025-02-27FY2024Parent Company Cash$0.8 billion18
2025-02-27FY2024Other Long Term Investments$4.6 billion18
2025-02-27FY2024Medical customers19,14718
2025-02-27FY2024Long Term Debt Scheduled Payments$48.5 billion18
2025-02-27FY2024Long Term Debt Due 2025$3.5 billion18
2025-02-27FY2024Investment Grade Debt Securities$8.1 billion18
2025-02-27FY2024Investment Commitments 2025$0.9 billion18
2025-02-27FY2024Investment Commitments$2.7 billion18
2025-02-27FY2024HCSC Transaction Initial Price$3.3 billion18
2025-02-27FY2024Future Service Commitments$1.5 billion18
2025-02-27FY2024Expected Capex 2025$1.4 billion18
2025-02-27FY2024Dividends from US Subsidiaries 2024$2.4 billion18
2025-02-27FY2024Dividends from US Subsidiaries 2023$1.2 billion18
2025-02-27FY2024Debt to Capitalization Ratio 202443.8%18
2025-02-27FY2024Debt to Capitalization Ratio 202340.1%18
2025-02-27FY2024Debt Securities Portfolio$9.4 billion18
2025-02-27FY2024Debt Securities 2023$9.9 billion18
2025-02-27FY2024Commercial Paper Outstanding$0.9 billion18
2025-02-27FY2024Commercial Mortgage Loan Portfolio$1.4 billion18
2025-02-27FY2024China Joint Venture Investment Portfolio$15.6 billion18
2025-02-27FY2024Cash and Short-Term Investments$7.6 billion18
2025-02-27FY2024Capital Expenditures 2024$1.4 billion18
2025-02-27FY2024Capital Expenditures 2023$1.6 billion18
2025-02-27FY2024Below Investment Grade Debt Securities$1.3 billion18
2025-01-302024-Q4Total Pharmacy Customers118,30417
2025-01-302024-Q4Total Medical Customers19,14717
2025-01-302024-Q4Total Customer Relationships182,21217
2025-01-302024-Q4Specialty and Care Services Adjusted Revenues, Q4 202423,471 (USD in millions)17
2025-01-302024-Q4Specialty and Care Services Adjusted Revenues, Full Year 202490,333 (USD in millions)17
2025-01-302024-Q4Specialty and Care Services Adjusted Income from Operations Pre-Tax, Q4 202494817
2025-01-302024-Q4Specialty and Care Services Adjusted Income from Operations Pre-Tax, Full Year 20243,42417
2025-01-302024-Q4Pharmacy Benefit Services Adjusted Revenues, Q4 202430,273 (USD in millions)17
2025-01-302024-Q4Pharmacy Benefit Services Adjusted Revenues, Full Year 2024111,822 (USD in millions)17
2025-01-302024-Q4Pharmacy Benefit Services Adjusted Income from Operations Pre-Tax, Q4 20241,19817
2025-01-302024-Q4Pharmacy Benefit Services Adjusted Income from Operations Pre-Tax, Full Year 20243,57717
2025-01-302024-Q4Evernorth Health Services Adjusted Revenues, Q4 202453,744 (USD in millions)17
2025-01-302024-Q4Evernorth Health Services Adjusted Revenues, Full Year 2024202,155 (USD in millions)17
2025-01-302024-Q4Evernorth Health Services Adjusted Income from Operations Pre-Tax, Q4 20242,14617
2025-01-302024-Q4Evernorth Health Services Adjusted Income from Operations Pre-Tax, Full Year 20247,00117
2025-01-302024-Q4Cigna Healthcare MCR, Q4 202487.9%17
2025-01-302024-Q4Cigna Healthcare MCR, Full Year 202483.2%17
2025-01-302024-Q4Cigna Healthcare Adjusted Revenues, Q4 202413,331 (USD in millions)17
2025-01-302024-Q4Cigna Healthcare Adjusted Revenues, Full Year 202452,914 (USD in millions)17
2025-01-302024-Q4Cigna Healthcare Adjusted Income from Operations Pre-Tax, Q4 202451117
2025-01-302024-Q4Cigna Healthcare Adjusted Income from Operations Pre-Tax, Full Year 20244,22917
2024-10-312024-Q3Pharmacy claim volume53115
2024-10-312024-Q3Medical customers19,04815
2024-10-312024-Q3Adjusted revenues63,699 (USD millions)15
2024-10-312024-Q3Total Pharmacy Customers119,99616
2024-10-312024-Q3Total Medical Customers19,04816
2024-10-312024-Q3Total Customer Relationships183,51416
2024-10-312024-Q3SG&A Expense Ratio5.6%16
2024-10-312024-Q3Medicare Part D Customers2,55716
2024-10-312024-Q3Dental Customers18,25116
2024-10-312024-Q3Cigna Healthcare Medical Care Ratio82.8%16
2024-10-312024-Q3Behavioral Care Customers23,66216
2024-10-312024-Q3Adjusted SG&A Expense Ratio5.5%16
2024-08-012024-Q2Unpaid claims and claim expenses Cigna Healthcare5202 (USD in millions)13
2024-08-012024-Q2Undrawn revolving credit capacity650013
2024-08-012024-Q2Total Pharmacy Customers122,47014
2024-08-012024-Q2Total Medical Customers19,04314
2024-08-012024-Q2Total Customer Relationships186,23214
2024-08-012024-Q2Shareholders' Equity per Share$147.8714
2024-08-012024-Q2Shareholders' Equity$41,33214
2024-08-012024-Q2SG&A Expense Ratio6.1%14
2024-08-012024-Q2Medicare Part D Customers2,56414
2024-08-012024-Q2Medical customers1904313
2024-08-012024-Q2Dental Customers18,33914
2024-08-012024-Q2Debt-to-Capitalization Ratio43.6%14
2024-08-012024-Q2Debt to capitalization ratio43.6%13
2024-08-012024-Q2Commercial paper outstanding79013
2024-08-012024-Q2Cigna Healthcare Medical Care Ratio82.3%14
2024-08-012024-Q2Cash and short-term investments7000 (USD in millions)13
2024-08-012024-Q2Behavioral Care Customers23,81614
2024-08-012024-Q2Adjusted SG&A Expense Ratio6.0%14
2024-05-022024-Q1Total Pharmacy Customers122,76712
2024-05-022024-Q1Total Medical Customers19,18412
2024-05-022024-Q1Total Customer Relationships186,75312
2024-05-022024-Q1Shareholders' Equity per Share145.0012
2024-05-022024-Q1Shareholders' Equity41,18112
2024-05-022024-Q1Pre-tax adjusted margin Evernorth2.9%11
2024-05-022024-Q1Pre-tax adjusted margin Cigna Healthcare10.1%11
2024-05-022024-Q1Medicare Part D Customers2,55812
2024-05-022024-Q1Medical customers1918411
2024-05-022024-Q1Medical care ratio Cigna Healthcare79.9%11
2024-05-022024-Q1Dental Customers18,44312
2024-05-022024-Q1Cigna Healthcare MCR79.9%12
2024-05-022024-Q1Behavioral Care Customers23,80112
2024-05-022024-Q1Adjusted Expense Ratio Evernorth2.1%11
2024-05-022024-Q1Adjusted Expense Ratio Cigna Healthcare20.5%11
2024-02-29FY2023Pre-Tax Adjusted Margin Other Operations16.1%10
2024-02-29FY2023Pre-Tax Adjusted Margin Evernorth4.2%10
2024-02-29FY2023Pre-Tax Adjusted Margin Cigna8.7%10
2024-02-29FY2023Overall Generic Fill Rate86.7%10
2024-02-29FY2023Network Generic Fill Rate86.9%10
2024-02-29FY2023Medical Care Ratio Cigna81.3%10
2024-02-29FY2023Home Delivery Generic Fill Rate85.3%10
2024-02-29FY2023Adjusted Expense Ratio Evernorth2.2%10
2024-02-29FY2023Adjusted Expense Ratio Cigna21.6%10
2024-02-29FY2023Medical customers19,78010
2024-02-022023-Q4U.S. Healthcare18.170 million9
2024-02-022023-Q4Total Pharmacy Customers98.6 million9
2024-02-022023-Q4Total Medical Customers19.8 million9
2024-02-022023-Q4Total Customer Relationships164.399 million9
2024-02-022023-Q4Medicare Part D2.550 million9
2024-02-022023-Q4International Health1.610 million9
2024-02-022023-Q4Dental18.543 million9
2024-02-022023-Q4Debt-to-Capitalization Ratio (December 31, 2023)40.1%9
2024-02-022023-Q4Cigna Healthcare Medical Care Ratio (Q4 2023)82.2%9
2024-02-022023-Q4Cigna Healthcare Medical Care Ratio (Full Year 2023)81.3%9
2024-02-022023-Q4Behavioral Care24.956 million9
2023-11-022023-Q3Total Revenues$49,0487
2023-11-022023-Q3Shareholders Net Income$1,4087
2023-11-022023-Q3Medical customers19,6077
2023-11-022023-Q3Adjusted revenues$49,0787
2023-11-022023-Q3Total Pharmacy Customers98,3258
2023-11-022023-Q3Total Medical Customers19,6078
2023-11-022023-Q3Total Customer Relationships164,1698
2023-11-022023-Q3Shareholders' Equity per Share$155.548
2023-11-022023-Q3Evernorth Health Services Adjusted Margin, Pre-Tax4.4%8
2023-11-022023-Q3Debt-to-Capitalization Ratio40.5%8
2023-11-022023-Q3Cigna Healthcare Medical Care Ratio80.5%8
2023-11-022023-Q3Cigna Healthcare Adjusted Margin, Pre-Tax9.6%8
2023-11-022023-Q3Adjusted SG&A Expense Ratio7.3%8
2023-08-032023-Q2Unpaid Claims and Claim Expenses - Cigna Healthcare5,336 (USD millions)5
2023-08-032023-Q2Total Pharmacy Customers98,6386
2023-08-032023-Q2Total Medical Customers19,5066
2023-08-032023-Q2Total Customer Relationships165,7036
2023-08-032023-Q2SG&A Expense Ratio7.1%6
2023-08-032023-Q2Medical customers19,5065
2023-08-032023-Q2Evernorth Adjusted Margin, Pre-Tax4.0%6
2023-08-032023-Q2Debt-to-capitalization ratio41.9%6
2023-08-032023-Q2Cigna Healthcare MCR81.2%6
2023-08-032023-Q2Cigna Healthcare Adjusted Margin, Pre-Tax9.2%6
2023-05-052023-Q1Total Pharmacy Customers98,7494
2023-05-052023-Q1Total Medical Customers19,4734
2023-05-052023-Q1Total Customer Relationships166,3844
2023-05-052023-Q1Share Repurchases YTD3.7 million shares4
2023-05-052023-Q1Medicare Part D Customers2,5414
2023-05-052023-Q1Medical customers19,4733
2023-05-052023-Q1Diluted Earnings Per Share4.243
2023-05-052023-Q1Dental Customers18,7314
2023-05-052023-Q1Debt-to-Capitalization Ratio42.2%4
2023-05-052023-Q1Cigna Healthcare MCR81.3%4
2023-05-052023-Q1Behavioral Care Customers26,8904
2023-05-052023-Q1Adjusted Revenues46,479 (USD in millions)3
Advertisement

Guidance Tracking (latest per metric/period · 25/50)#

All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.

For periodGuided onMetricGuidedVerdictDirectionSource
FY20262026-02-05EPS (non-GAAP)30.45pendingraised30
FY20262026-02-05Tax rate~19%pendinginitiated25
FY20262026-02-05Capex~1,300pendinginitiated25
FY20262026-02-05Evernorth Adjusted Income from Operations, Pre-Tax6,900pendingconfirmed28
FY20262026-02-05Cigna Healthcare Adjusted Income from Operations, Pre-Tax4,525pendingraised28
FY20262026-02-05Cigna Healthcare Medical Care Ratio83.7–84.7%pendingconfirmed28
FY20262026-02-05Adjusted Income from Operations7,950pendinginitiated25
FY20262026-02-05Adjusted Revenues~280,000pendinginitiated25
FY20262026-02-05Adjusted SG&A Expense Ratio~5%pendinginitiated25
FY20262026-02-05Cash Flow from Operations~9,000pendinginitiated25
FY20262026-02-05Shareholder Dividends~1,600pendinginitiated25
FY20262026-02-05Total Medical Customers~18.1pendinginitiated25
FY20252025-05-02EPS (non-GAAP)29.6confirmed24
FY20252025-05-02Evernorth Adjusted Income from Operations, Pre-Tax7,200confirmed22
FY20252025-05-02Cigna Healthcare Adjusted Income from Operations, Pre-Tax4,125confirmed22
FY20252025-05-02Cigna Healthcare Medical Care Ratio83.2–84.2%confirmed22
2025-Q42025-01-30Tax rate~19%initiated17
2025-Q42025-01-30Capex~1,400initiated17
2025-Q42025-01-30Adjusted Income from Operations7,900raised17
2025-Q42025-01-30Adjusted Revenues252,000initiated17
2025-Q42025-01-30Adjusted SG&A Expense Ratio~5.4%initiated17
2025-Q42025-01-30Cash Flow from Operations~10,000initiated17
2025-Q42025-01-30Shareholder Dividends~1,600initiated17
2025-Q42025-01-30Weighted Average Shares Outstanding266–270initiated17
2025-Q42025-01-30Total Medical Customers~18.1initiated17
FY20242024-05-02Adjusted Income from Operations, Pre-Tax (Evernorth)7,000confirmed12
FY20242024-05-02Adjusted Income from Operations, Pre-Tax (Cigna Healthcare)4,775raised12
FY20242024-05-02Medical Care Ratio81.7–82.5%confirmed12
FY20242024-02-02EPS (non-GAAP)28.4confirmed16
FY20242024-02-02Tax rate20.5–21%confirmed12
FY20242024-02-02Capex~1,500confirmed9
FY20242024-02-02Evernorth Adjusted Income from Operations, Pre-Tax7,000confirmed16
FY20242024-02-02Cigna Healthcare Adjusted Income from Operations, Pre-Tax4,775confirmed16
FY20242024-02-02Cigna Healthcare Medical Care Ratio81.7–82.5%confirmed16
FY20242024-02-02Adjusted Income from Operations8,065raised12
FY20242024-02-02Adjusted Revenues235,000confirmed12
FY20242024-02-02Adjusted SG&A Expense Ratio~6.1%confirmed12
FY20242024-02-02Cash Flow from Operations11,000confirmed12
FY20242024-02-02Weighted Average Shares Outstanding282–286confirmed12
FY20242024-02-02Total Medical Customers~19.3confirmed12
FY20242024-02-02Shareholder Dividends~1,550confirmed9
FY20232023-11-02Cash Flow from Operations10,500raised8
FY20232023-11-02Total Medical Customer Growth1,600,000raised8
FY20232023-08-03Adjusted Revenues192,000raised8
FY20232023-05-05Adjusted Income from Operations, Pre-Tax6,400initiated8
FY20232023-02-03EPS (non-GAAP)24.75raised8
FY20232023-02-03Tax rate21–21.5%confirmed1
FY20232023-02-03Adjusted Income from Operations7,360confirmed6
FY20232023-02-03Medical Care Ratio81.5–82%confirmed8
FY20232023-02-03Adjusted SG&A Expense Ratio~7.3%confirmed1
Advertisement

Development#

A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.

FY2026

The Cigna Group reported total revenues of $68.5 billion in Q1 2026 (+5% year-over-year) and $71.7 billion in Q2 2026 (+7%), with growth in both periods driven by Evernorth Health Services and, in Q2, also Cigna Healthcare 28 30. Shareholders' net income rose 25% in Q1 to $1,654 million and 8% in Q2 to $1,660 million, while adjusted income from operations per share increased 12% and 6% respectively, supported by two upward revisions to full-year guidance reaching at least $30.45 per share by July 2026 28 30. The HCSC transaction–completed March 19, 2025, divesting Medicare Advantage and related businesses–reduced Cigna Healthcare premiums 23% year-over-year in Q1 2026 and lowered the medical care ratio by 240 basis points to 79.8% primarily as a base effect of that divestiture, while Cigna Healthcare adjusted income from operations increased 18% in Q1 and 17% in Q2 driven by premium rate increases and improved U.S. Employer margins 27 29 30. In April 2026, the company announced a planned exit from the Individual and Family Plans medical business effective January 1, 2027 30. Within Evernorth Health Services, pharmacy revenues grew 11% in Q1 and 7% in Q2, though Pharmacy Benefit Services adjusted income from operations declined 28% in Q1 and 27% in Q2, reflecting expected lower contributions from large client relationships and client-focused initiatives 27 28 29 30.

FY2025

The Cigna Group reported full-year 2025 revenues of $274.9 billion, an increase of 11% year-over-year, driven primarily by growth in Evernorth Health Services, where pharmacy revenues rose 17% to $216,672 million (26). On March 19, 2025, the company completed the divestiture of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for $4.9 billion in cash proceeds, reducing total medical customers by 5% to 18,118 thousand (26). Shareholders' net income increased 73% to $5,957 million ($22.18 per share), primarily reflecting the absence of a non-cash impairment of VillageMD equity securities recorded in 2024; on an adjusted basis, income from operations increased 4% to $8,014 million ($29.84 per share) (26). The Cigna Healthcare segment's medical care ratio rose 120 basis points to 84.4% for the full year, primarily driven by the Individual and Family Plans business (26). In Q3 2025, Evernorth Health Services announced a transformational rebate-free pharmacy benefit model, and the company subsequently established a 2026 adjusted income from operations outlook of at least $7.950 billion ($30.25 per share) (24, 25).

FY2024

The Cigna Group reported FY2024 total revenues of $247.1 billion, a 27% increase from 2023, driven primarily by 32% growth in Evernorth Health Services following the onboarding of Centene Corporation at the start of the year and strong specialty volume growth across pharmacy and specialty businesses 17 18. Adjusted income from operations rose 4% to $7.7 billion ($27.33 per diluted share), as Evernorth Health Services earnings grew 9% while Cigna Healthcare adjusted income from operations declined 6% due to a higher medical care ratio 17. Shareholders' net income of $3.4 billion ($12.12 per diluted share) was materially reduced by $2.7 billion in aggregate non-cash after-tax investment losses from successive impairments of VillageMD equity securities recorded across 2024 17. In January 2024, the Company entered a definitive agreement to divest its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for approximately $3.7 billion, with closing expected in Q1 2025 17 18. The Cigna Healthcare medical care ratio increased 190 basis points to 83.2% for the full year, primarily driven by higher stop loss medical costs 17 18.

FY2023

The Cigna Group reported full-year 2023 total revenues of $195.3 billion, up from $180.5 billion in 2022, with Evernorth Health Services contributing adjusted revenues of $153.5 billion and Cigna Healthcare contributing adjusted revenues of $51.2 billion (9, 10). Adjusted income from operations reached $7.4 billion, or $25.09 per share, compared with $7.3 billion, or $23.36 per share, in 2022, driven by higher earnings in both reportable segments (9). Shareholders' net income of $5.16 billion ($17.39 per share) was reduced by an estimated loss recognized in connection with the definitive agreement to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to Health Care Service Corporation for $3.3 billion cash, partially offset by foreign deferred tax benefits (10, 18). Medical customers grew 10% to 19.8 million and pharmacy customers grew 5% to 98.6 million at December 31, 2023, while the company repurchased approximately $2.3 billion in shares and declared a 14% increase in the quarterly dividend (9). Strategic investments during 2023 included a $2.7 billion preferred equity stake in VillageMD and a minority interest in CarepathRx Health Systems Solutions, alongside capital expenditures of $1.6 billion (10).

Advertisement

Sources: official investor relations documents#

All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.

45 documents · 2019 – 2026 · SEC EDGAR (USA)
#Document typePublishedLink
#1 / #1018-K-EX99.12023-02-03Open
#210-K2023-02-23Open
#310-Q2023-05-05Open
#48-K-EX99.12023-05-05Open
#510-Q2023-08-03Open
#68-K-EX99.12023-08-03Open
#710-Q2023-11-02Open
#88-K-EX99.12023-11-02Open
#98-K-EX99.12024-02-02Open
#1010-K2024-02-29Open
#1110-Q2024-05-02Open
#12 / #1128-K-EX99.12024-05-02Open
#1310-Q2024-08-01Open
#148-K-EX99.12024-08-01Open
#1510-Q2024-10-31Open
#168-K-EX99.12024-10-31Open
#178-K-EX99.12025-01-30Open
#1810-K2025-02-27Open
#1910-Q2025-05-02Open
#208-K-EX99.12025-05-02Open
#2110-Q2025-07-31Open
#228-K-EX99.12025-07-31Open
#2310-Q2025-10-30Open
#248-K-EX99.12025-10-30Open
#25 / #1258-K-EX99.12026-02-05Open
#2610-K2026-02-26Open
#2710-Q2026-04-30Open
#28 / #1288-K-EX99.12026-04-30Open
#2910-Q2026-07-30Open
#30 / #1308-K-EX99.12026-07-30Open
Older sources (+15)
#Document typePublishedLink
#20110-K2019-02-28Open
#20310-Q2019-02-28Open
#20410-K2019-02-28Open
#20810-K2019-02-28Open
#20510-Q2019-05-02Open
#20210-Q2019-08-01Open
#20610-Q2019-08-01Open
#20710-Q2019-10-31Open
#21210-K2020-02-27Open
#20910-Q2020-05-07Open
#21010-Q2020-08-06Open
#21110-Q2020-11-05Open
#21310-Q2021-05-07Open
#21410-Q2021-08-05Open
#21510-Q2021-11-04Open

FAQ#

Is there a management forecast (guidance) for FY2026?

Yes. Management has issued targets for FY2026, including EPS (non-GAAP). The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.

Does The Cigna Group pay a dividend?

The filings report on the dividend; most recent entry: dividends paid $2.4 billion (FY2024) (as reported, no assessment of our own). Details with source links are in the report chapters.

Where can I find the official investor relations documents of The Cigna Group?

The sources chapter links all 50 original filings used (SEC filings) with type, publication date and a direct link; every figure in the report carries a source number.

More reports#

Advertisement